Roche: Longer-term Data With Vabysmo Support Its Continued U

SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY) reported two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo (faricimab) in neovascular

Related Keywords

Levi Garraway , Head Of Global Product Development , More Such Health News , Chief Medical Officer , Global Product Development , Roche , Longer , Term , Data , Ith , Vabysmo , Support , Ontinued , People , Neovascular ,